[{"id":"bf08ec17-5171-4452-9f04-c52123ce8ca4","acronym":"QUILT-3.017","url":"https://clinicaltrials.gov/study/NCT03476681","created_at":"2021-10-22T17:53:23.788Z","updated_at":"2024-07-02T16:35:03.580Z","phase":"Phase 1/2","brief_title":"Study of NEO-201 in Solid Tumors Expansion Cohorts","source_id_and_acronym":"NCT03476681 - QUILT-3.017","lead_sponsor":"Precision Biologics, Inc","biomarkers":" EGFR • PD-L1 • BRAF • TMB • MSI • ROS1 • ALK1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600","tags":["EGFR • PD-L1 • BRAF • TMB • MSI • ROS1 • ALK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • NEO-201"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 01/18/2019","start_date":" 01/18/2019","primary_txt":" Primary completion: 10/15/2025","primary_completion_date":" 10/15/2025","study_txt":" Completion: 10/15/2026","study_completion_date":" 10/15/2026","last_update_posted":"2024-05-15"}]